Fezolinetant

Chemical formula: C₁₆H₁₅FN₆OS  Molecular mass: 358.101 g/mol  PubChem compound: 117604931

Therapeutic indications

Fezolinetant is indicated for:

Moderate to severe vasomotor symptoms associated with menopause

Population group: women, only adults (18 - 65 years old)

Abnormal vasomotor function and additionally Menopause present

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Fezolinetant is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Moderate CYP1A2 inhibitors, strong CYP1A2 inhibitors

at least one of
Moderate CYP1A2 inhibitors
Strong CYP1A2 inhibitors

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: VEOZA Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈